… in patients with adenocarcinoma, and as a consequence seven EGFR mutated patients in our
study (1.5%) received erlotinib as first-line … histologies at the time of second line treatment. …

… and toxicities of erlotinib as first-line treatment, especially for elderly patients with advanced
… of erlotinib as first-line treatment in Asian elderly patients with advanced NSCLC. Patients …

… In Europe, erlotinib is approved for the first-line treatment of patients with locally advanced
or metastatic NSCLC with EGFR activating mutations, for switch maintenance treatment in …

… therapy, and nine cases were treated as third-line therapy. Nine patients (29.0%) in the
present study were treated with erlotinib as fourth-line or later therapy. …

… and safety of first-line erlotinib versus chemotherapy in European patients with confirmed
EGFR … The trial has met its primary endpoint of improved progression-free survival for erlotinib …

… rates and longer progression-free survival in patients harbouring an EGFR mutation. Two …
the role of first-line erlotinib in patients with the mutations. Erlotinib has also been evaluated in …

… Patients who used either gefitinib or erlotinib as second-line therapy were excluded. We
did … or erlotinib as second-line therapy because erlotinib gained approval as second-line …

… Erlotinib is effective in pretreated patients, and can be given second-line in patients not …
, and in all patients as third-line treatment after failure of second-line chemotherapy. Gefitinib …

… patients who … patients in this study received erlotinib as a fourth-line or subsequent treatment,
the results from this study were similar to those of clinical studies. We deduce that erlotinib …

… of second-line pemetrexed followed by third-line erlotinib (PE… Patients and Methods: We
analyzed data of 57 patients with … patients treated with second-line erlotinib followed by third-…